Navigation Links
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Brachytherapy market. Brachytherapy is emerging as an effective treatment option for cancer patients with the market projected to reach $1.6 billion by 2015. Primary growth drivers include rising prevalence of cancer, growing medical awareness, improving success rate of brachytherapy, and advent of advanced radiation technologies.

San Jose, CA (PRWEB) June 22, 2009 -- Rising proportion of cancer population in both developed and developing countries is expected to enhance the demand for brachytherapy for cancer treatment. In particular, brachytherapy has emerged as the effective treatment option for prostate cancer patients, who have failed to achieve desirable results through surgery or external radiation therapy. With long-term clinical data offering support for the effectiveness of brachytherapy in reducing size of the tumor, the therapy is expected to gain strength. With indications for brachytherapy ranging from prostate cancer, head and neck cancer, cervical cancer, and breast cancer to coronary applications, the rapidly aging world population represents a strong demographic growth driver.

The United States represents the largest as well as the fastest growing market for brachytherapy. In the United States, increasing incidence of cancer cases and related mortality rates are contributing to the increasing demand for brachytherapy, as stated in the new report. Rising awareness about risks of surgery and external radiation therapy are fostering advancements in technologies and products for less invasive treatment for cancer. Growing uptake of brachytherapy is also attributed to the increasing success rates of prostate brachytherapy, breast brachytherapy, and head and neck brachytherapy procedures. Driven by the minimally invasive nature of the procedure, Implantable Prostate Seed Therapy is expected to continue posting healthy gains in the market.

Further, balloon brachytherapy for breast cancer treatment is expected to gain rapid acceptance among patients and physicians alike. Post-Operative Brachytherapy market is the fastest growing segment. Growing concerns over rising cancer levels, increasing awareness about adverse effects of EBRT, constant improvements in technologies and devices, and wider acceptance of brachytherapy are expected to boost prospects in the European post-surgical brachytherapy market.

Competition in the brachytherapy market is intensifying, particularly in the implantable prostate seed segment with Oncura Corp., CR Bard, NAS Medical, Theragenics Corporation, and Xoft, competing for a share of the lucrative market. Major players profiled in the report include Best Medical International Inc, BrachySciences Inc, C. R. Bard Inc, Core Oncology, Cytogen Corporation, Cytyc Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, International Brachytherapy SA, Oncura, Inc., Theragenics Corporation Sirtex Medical Ltd, Varian Medical Systems Inc, Xoft Inc, among several others.

"Brachytherapy: A US and European Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of prevailing market issues and trends, competitive scenario, and recent industry activity in the brachytherapy market. Analytics for the period 2005-2015 provide a comprehensive understanding of markets including the United States and Europe. The markets are analyzed in terms of Number of Procedures (Thousands) and Annual Revenues (US$ Million) for the segments - Implantable Prostate Seed and Post-Surgical Brachytherapy.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at)
Web Site

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Varian Medical Systems to Unveil RapidArc(TM) Volumetric Arc Therapy and Other Products Designed to Speed Delivery of Precision Radiotherapy and Brachytherapy
2. FDA Clears New Skin and Surface Treatment Applicator for Use With Xofts Axxent(R) Electronic Brachytherapy (eBx) System
3. R&D Magazine Selects Xoft Axxent(R) Electronic Brachytherapy System as Editors Choice Innovation Award Winner
4. High dosage brachytherapy obtains excellent results in head and neck tumors
5. Prostate Cancer Patients in US and Europe Receive Treatments Using Enhanced Seed Prostate Brachytherapy Software
6. Xoft Receives Health Canada Regulatory Approval for the Axxent(R) Electronic Brachytherapy System
7. Varian Medical Systems Introduces Fast and Precise Brachytherapy Planning System at GEC-ESTRO in Portugal
8. New Fast and Precise Treatment Planning System Among Varian Medical Systems Highlights at American Brachytherapy Society 2009 Meeting
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
Related Image:
US Brachytherapy Market to Reach $1.6 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology: